Upfront payments.

ARIAD has solely licensed the applications of the ARGENT technology for regulated gene therapy to ReGenX. The NAV technology is founded on over ten years of analysis by the founders of ReGenX, funded partly by GlaxoSmithKline plc and predicated on a long-standing commitment by the University of Pennsylvania. ReGenX initially plans to develop the ARGENT products for specific ocular illnesses, metabolic disorders, and infectious illnesses, in each case where precise control of protein production is required to achieve the desired patient benefit. Initial applications will involve the use of another one of ARIAD’s portfolio of small-molecule dimerizer medicines, AP22594, which includes been optimized for these uses.

5.8 %), as are white males in comparison to white females . Related StoriesBreakthrough research to be offered at AAO-HNSF 2015 Annual Meeting & OTO EXPOResearch shows one in three young men in China could die from tobacco useTobacco cessation system needs to be more trusted for teens with substance abuse issues: Study ‘There is more to tobacco use than smokes and we can no longer ignore the use of cigars,’ stated Erika Trapl, PhD, associate director of the PRCHN.5.8 %), as are white males in comparison to white females . Related StoriesBreakthrough research to be offered at AAO-HNSF 2015 Annual Meeting & OTO EXPOResearch shows one in three young men in China could die from tobacco useTobacco cessation system needs to be more trusted for teens with substance abuse issues: Study ‘There is more to tobacco use than smokes and we can no longer ignore the use of cigars,’ stated Erika Trapl, PhD, associate director of the PRCHN.